22a976e9-fa0c-4c08-aa5a-f0cb09dca87d.jpeg
45900f4b-9321-42a7-869b-36ebca512728.jpeg
tell me about the prescription
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
This looks like a follow-up nephrology prescription for a CKD patient. Piecing together both notes:
Background (from the Sir Ganga Ram Hospital note - Dr. Manish Malik, Nephrology)
- Patient: Sachin Garg, 38M
- Diagnosis: CKD G4A3 (advanced chronic kidney disease with heavy albuminuria), noted as likely IgA nephropathy with segmental sclerosis
- Home BP running ~150/97, reported "OK" at home
- Advised: USG KUB, urine ACR, vitamin D level, and follow-up
The "Prime Consult" prescription (this image)
Heading "Rx, BP target 120-130/80-88" tells you the goal of this regimen is BP control alongside kidney protection. The medicines, as best I can read the handwriting:
| Drug (as written) | Likely identity | Why it's used in this context |
|---|---|---|
| Dapmel 10 | Dapagliflozin 10 mg | SGLT2 inhibitor - slows CKD progression, reduces proteinuria |
| Kerendia 10 | Finerenone 10 mg | Nonsteroidal mineralocorticoid receptor antagonist; the FIDELIO/FIGARO trials showed it cuts risk of CKD progression (sustained eGFR decline, kidney failure) and cardiovascular events by ~18% (Comprehensive Clinical Nephrology, 7th ed.; National Kidney Foundation Primer on Kidney Diseases, 8e) |
| Telmikind 40 | Telmisartan 40 mg | ARB - BP control and reduces proteinuria/renal protection |
| Thyronorm 100 mcg | Levothyroxine 100 mcg | Thyroid hormone replacement (hypothyroidism) |
| Crestor-type tablet ("...low") | Likely a statin (e.g., rosuvastatin) | Cardiovascular risk reduction, standard in CKD |
| "Enprocor"/similar - int. | Possibly Sacubitril/Valsartan (Entresto) | ARNI used for cardio-renal protection/heart failure risk in CKD (Katzung's Pharmacology; Goldman-Cecil Medicine) |
| Sodibicarb-EC (or similar "-EC") | Sodium bicarbonate, enteric-coated | Corrects metabolic acidosis, a common complication of CKD, and may slow progression (Brenner & Rector's The Kidney) |
Bottom-left annotations:
- Labs to repeat: KFT/eGFR, HbA1c, lipid profile ("HBsAg", "UACR")
- Follow-up: in 15-20 days
- Diet instruction: circled note reads like "Diet -> K+ (potassium) restricted" - i.e., a low-potassium renal diet, standard advice for CKD G4 patients who are prone to hyperkalemia (especially since finerenone and ARBs both raise potassium risk).
Important caveat
Several drug names are genuinely hard to make out with certainty in handwriting (especially the statin and the "Enprocor/Entresto" line) - I've matched them to the closest real drug names that fit a CKD/cardio-renal protection regimen, but I can't be 100% certain from the image alone. Before dispensing or taking these medications, please confirm the exact drug names and doses with the prescribing doctor (Prime Consult, 9650941359) or a pharmacist, particularly because:
- Finerenone and RAAS blockers (Telmisartan) together significantly raise the risk of hyperkalemia, which is why potassium and renal function need close monitoring (hence the KFT/eGFR recheck and K+-restricted diet).
- Any dose/frequency ambiguity in a CKD stage 4 patient carries real safety risk (drug accumulation, hyperkalemia, hypotension).
If you want, I can help draft a clear question list to confirm these drug names/doses when you call the clinic.
This is a shared conversation. Sign in to Orris to start your own chat.